GoldmanSmallCap's profile picture. We publish sponsored and non-sponsored market and small cap research. Perform due diligence and refer to our disclosures before investing.

GoldmanSmallCap

@GoldmanSmallCap

We publish sponsored and non-sponsored market and small cap research. Perform due diligence and refer to our disclosures before investing.

Great new piece on $RGBP on stockhouse.com. Describes positioning and potential in very direct way. stockhouse.com/blogs/savings/… Here is our update from yesterday: goldmansmallcapresearch.com/opportunity-re…


New update out in $RGBP. Clarity on Phase I trial commencement progress and other info could come next week with presentation at Emerging Growth Conference. goldmansmallcapresearch.com/opportunity-re…


Great info from @TheRegenBio. We believe that $RGBP could make a big jump in early 2026 based on upcoming events and peer group. Peer group has already begun their moves to the upside. New update from us coming soon. goldmansmallcapresearch.com/opportunity-re…


New report on $RGBP. Phase I launch imminent. Trades at substantial discount to peer group which should change with launch. Report highlights potential rev and peer group. goldmansmallcapresearch.com/opportunity-re…


$RGBP on verge of major event. Text from our update is below: As evidenced by recent comments from Regen on X, “the company is currently in discussion financing the Phase I clinical trials for HemaXellerate™”. We infer that management is talking with one or more parties who see…


$RGBP made nice base here, great entry point. Terrific news of late with more to come. Tremendous upside as valuation is a major discount to peers also migrating to clinical stage. Current mkt cap reflects just the IP, in our view. goldmansmallcapresearch.com/opportunity-re… #Biotech #Smallcaps


Transformative new press release from $SIGY. Entering massive cardiovascular industry with novel strategy targeting end stage renal disease patients who are at most risk of cardiac events. finance.yahoo.com/news/sigyn-the… goldmansmallcapresearch.com/wp-content/upl…


New update on $RGBP. Stock at bargain basement prices. Does not reflect typical valuation afforded biopharmas at this stage. Near term milestones set to drive stock back to prior levels. goldmansmallcapresearch.com/opportunity-re… #biopharma #Smallcaps


$RGBP presenting today at 1:45PM EST at Emerging Growth Conference. Likely to learn key new info biz info. Sign up at emerginggrowth.com. goldmansmallcapresearch.com/opportunity-re…


New report on innovative green tech co. $CLGOF. Also trades on CSE $CGII. Underfollowed, undervalued, but not for long. New initiatives to drive profile, sales, and valuation. goldmansmallcapresearch.com/opportunity-re… $SLB $HAL #GreenTech #SmallCaps


New update on $RGBP. Important news yesterday prompted due dili. Value of potential orphan drug designation much greater than we thought. NIH study noted median orphan drug price is $218K. For every 1000 patients prescribed one, that’s $218M in sales. goldmansmallcapresearch.com/opportunity-re…


Technical Analysis Alert: $RGBP closed above its 200 and 50 MA on Friday on strong volume. A very bullish sign. Seems like this trend is just beginning and we could have a strong week. goldmansmallcapresearch.com/opportunity-re… youtu.be/Sr8wmOXcfPQ?si…

GoldmanSmallCap's tweet card. RGBP: Phase I Clinical Trial Launch a Major Driver for Innovative...

youtube.com

YouTube

RGBP: Phase I Clinical Trial Launch a Major Driver for Innovative...


New report and video on $RGBP. Migrating from preclinical to clinical stage with Phase I candidate. Stock grossly undervalued vs similar stage firms. Deep pipeline & IP. Price tgt 5x higher than closing price. goldmansmallcapresearch.com/opportunity-re… youtu.be/Sr8wmOXcfPQ?si… #biotech #SmallCaps

GoldmanSmallCap's tweet card. RGBP: Phase I Clinical Trial Launch a Major Driver for Innovative...

youtube.com

YouTube

RGBP: Phase I Clinical Trial Launch a Major Driver for Innovative...


A new Seeking Alpha piece is bullish on clean energy stocks. Notes that iShares Global Clean Energy ETF $ICLN up 26% since market lows. We believe that microcaps like $AECX poised to follow larger brethren goldmansmallcapresearch.com/opportunity-re… youtu.be/3GWGbfs17Qw?si… #Smallcaps

GoldmanSmallCap's tweet card. Clean Energy Innovator AECX Poised for Rare Growth Opportunity

youtube.com

YouTube

Clean Energy Innovator AECX Poised for Rare Growth Opportunity


New video highlighting emerging med device player $SIGY. Stock very undervalued and upcoming milestones set to take stock to new levels. No approved therapies for multi billion dollar markets. youtu.be/nOPC8BWOg80?si… goldmansmallcapresearch.com/opportunity-re… #SmallCaps #sepsis

GoldmanSmallCap's tweet card. SIGY: Poised to Transform the Medical Device Industry

youtube.com

YouTube

SIGY: Poised to Transform the Medical Device Industry


$AECX poised to record first sales this year-$3.8M and grow to $12M next year as they make big splash in high profile market. Watch the video or read our report: youtu.be/3GWGbfs17Qw?si… goldmansmallcapresearch.com/opportunity-re… #StocksInFocus #CleanEnergy

GoldmanSmallCap's tweet card. Clean Energy Innovator AECX Poised for Rare Growth Opportunity

youtube.com

YouTube

Clean Energy Innovator AECX Poised for Rare Growth Opportunity


New report on $AECX. Rare revenue and other milestones ahead. Stock underfollowed and undervalued. Major upside ahead. Great clean energy integration positioning to establish and operate microgrid network in upstate NY. goldmansmallcapresearch.com/opportunity-re…


New report on $SIGY. Underfollowed, undervalued co developing treatment for sepsis and end stage renal disease. Major near term milestones ahead to raise valuation. 6 Mo. Price target is $9 vs $2.75 close. goldmansmallcapresearch.com/opportunity-re… #stocks #SmallCaps $CTSO $EDT.TO


Loading...

Something went wrong.


Something went wrong.